Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

This study was designed to evaluate in healthy volunteers the renal hemodynamic and tubular effects of the orally active angiotensin II receptor antagonist losartan (DuP 753 or MK 954).

Why It Was Studied

The two 6-day diet periods were separated by a 5-day washout period.

Who Took Part

The abstract describes 23 subjects taking part.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Angiotensin II.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Aldosterone, Angiotensin II, Biphenyl Compounds, Blood Pressure, Electrolytes, Glomerular Filtration Rate and Hemodynamics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 23 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.